Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Jesspro, that article was right on the money!
KZR results won’t matter until they pass phase three, by then AUPH will be in full distribution with IP protection until 2027-28.
Right on Jess pro, I think rum runner hit the rum Hit the bottle early today
Most money managers have issues with spec stocks...if you invested in NVAX and Moderna, you’ll recall the bearish statements on those biotechs as well.For those of us who really follow these types of stocks, we know what good news can do to the price, it’s just a matter of time before INO’s turn.
Good point GMA!
If you guys read form F10 on Aurinia’s website, it gives a really good incite into marketing, distributing and bringing the company into the U.S.You can see by the form Auph is positioning the company for success, check it out.
Also, I found a good article from Jim Cramer on these types of offerings:
With interest rates at or near historic lows, “Companies have been issuing equity to either pay down debt or to refinance it with cheaper debt that carries a lower interest rate,” Cramer said.
“The money saved on those interest payments falls straight to the bottom line improving the health of the balance sheet. In turn shares rally.”
As an example, Cramer pointed out the many secondaries recently made by REITs. Ultimately those secondaries proved to be beneficial to shareholders.
“That’s because the money the companies raised was used to pay down expensive debt or to refinance it with cheaper debt that carried a lower interest rate,” Cramer added.
And the secondaries had other bullish effects, too.
“In some cases, the ratings agencies upgraded the firms because they carried less debt. In turn, the upgrade prod
Amen Gregg, stock up !
I’m with cervelo on this
Thanks Rab!
Anybody tuning in on this tomorrow?
presentation at the ASCO 2020 Virtual Scientific Program, May 29-31, 2020.
Participating in the webinar event will be INOVIO leadership and world-renowned scientists, including:J. Joseph Kim, Ph.D., INOVIO President, CEO and Director
David B. Weiner, Ph.D., Executive Vice President and Director, Vaccine Center, The Wistar Institute; INOVIO Director and Scientific Advisory Board Member
Stanley A. Plotkin, M.D., Emeritus Professor, The Wistar Institute and the University of Pennsylvania; INOVIO Scientific Advisory Board Member
Kate E. Broderick, Ph.D., INOVIO Senior Vice President, Research and Development, Team Lead for COVID-19 Vaccine Development
Jeffrey Skolnik, M.D., INOVIO Vice President, Clinical Development, Oncology
David Reardon, M.D., Clinical Director, Center for Neuro-Oncology, Dana-Farber Cancer Institute; Coordinating Principal Investigator of GBM-001/INO-5401 Phase 1/2 Investigator
The event will be held virtually and include a Q&A. To register, please go to INOVIO's website athttp://ir.inovio.com/events-and-presentations/default.aspx. An archived version of the presentation will be made available through the INOVIO Investor Relations events page following the event.
Strictly An American company now, Md?
I’m with Greggon this, totally flying under the radar, nobody wants to go to the doc with Cvid issues, once that clears, this will run.
Excellent point John, , seems that was an article done by somebody who had too much time on his hands.....Ha!
I heard on the news last night, breast cancer screenings are down 94% since covid, now I understand why we’re just dancing around 35 right now.
68 is too young....
Amen Zeppo and sorry to hear the bad news Bruce.
Cheers Gregg!!
And we broke 35 today,
Stock will hit the mid 30’s easily with drug approval, and mid 20’s well before that.
I wish you would have told me about that yesterday
Amazes me how this stock is flying under the radar, as soon as a well known analyst covers AUPHIt will be back in the 20’s, then who knows how high once production begins.
Article released 5 days ago.
In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Immunomedics, with a price target of $54.00. The company’s shares closed last Wednesday at $32.20, close to its 52-week high of $33.03.
I don’t think 100, but 60 bucks a share after the first week of June. Mdbl1, I couldn’t agree more, did you ever think you’d be able to buy a stock that cures breast cancer for under 50 bucks a share,IMO, This is being overshadowed by the covid vaccines and fear of going to the doctors office right now.
VEGAS STOCKS...IMMU up another buck today, CYDY dropped below 3 in the 2’s, I’ve been giving you free advice, be smart, jump in buddy!
Vegas stocks , IMMU up ANOTHER 5 bucks since your last message, CYDY down again, looks like it will be in the 2’s next week at this rate.You should have bailed on CYDY and taken my advice and purchased IMMU.I was trying to help you out bud.
Hilarious, don’t quit your day job Vegas Stocks.
IMMU received FDA approval last night after hours, it’s only up 5 bucks today, what a steal!!
Do people know this is a cure for breast cancers?
Good DD Purple Jesus, I completely agree with yo7!
In March 2020, INOVIO received a new $5 million grant from the Bill and Melinda Gates Foundation anticipated to fund accelerated testing and scale up of INOVIO's CELLECTRA® 3PSP proprietary smart device for the intradermal delivery of INO-4800, in order to support large scale manufacturing of INO-4800 doses by end of 2020.
INO’s vaccine delivery system runs on 2-AA battery’s and will be simple to use Inovio is "the only company with a phase 2 vaccine for a related coronavirus that causes Middle East Respiratory Syndrome (MERS)."
Did you guys see the video of INO’s president and CEO talking to President Trump about having a vaccine ready, but needing help to scale and distribute .....The amount of vaccine that will need to be administered is mind boggling to me, millions ....billions?
Go to: www.frankcruzlaw.com to join the class action lawsuit against Citron, this could be huge for INO,
Agreed Clutch, and Rolo thank you for your service, along with anyone else on this board who serve(d)!
Time to reload, this price is ridiculously low!
Think about it: You're a savvy investor with 6.8 million dollars, why buy this stock at this time when there are countless other investments out there.
COCP just raised nearly 7 million Dollars , I think this is a solid move considering a company this small . How would they be able to scale a vaccine globally or even nationally. This is a much greater position to be in, considering the investors paid 1.35 a share , panic must be the only thing dragging this stock to these levels?